- ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.
Pfizer will showcase third-quarter results, but investors will be more focused on the potential for its Inflectra drug, as well as its outlook on M&A.
The thwarted Medivation bidder lifts its full-year earnings estimates and announces a share buyback program.
Strong demand drives results and gains for Boeing, Akamai and others.
Britain's largest pharmaceuticals company reports growth in its HIV medicines business as it submits a shingles vaccine for FDA approval.